Sodium bisulfite
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Sodium bisulfite is an ingredient in parenteral nutrition products for patients with severe liver disorders.
- Generic Name
- Sodium bisulfite
- DrugBank Accession Number
- DB14015
- Background
Sodium bisulfite has been used externally for parasitic skin diseases and as a gastrointestinal antiseptic.
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 104.061
Monoisotopic: 103.954409263 - Chemical Formula
- HNaO3S
- Synonyms
- Bisulfite de sodium
- Natriumbisulfit
- Natriumhydrogensulfit
- primäres Natriumsulfit
- saures Natriumsulfit
- Sodium bisulfite
- sodium bisulphite
- sodium hydrogen sulfite
- sodium hydrogensulfite
- External IDs
- E222
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to manage Hepatic encephalopathy (he) •••••••••••• ••••••••• Used in combination to manage Hepatic encephalopathy (he) •••••••••••• ••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareCisplatin The therapeutic efficacy of Cisplatin can be decreased when used in combination with Sodium bisulfite. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image HEPATAMINE %8 500 ML(SETLI) Sodium bisulfite (0.01 %) + Ademetionine (0.24 %) + Adenine (0.8 %) + Ascorbic acid (0.6 %) + Aspartame (0.9 %) + Biotin (0.1 %) + Calcifediol (0.9 %) + Cysteine (0.066 %) + Lysine (0.61 %) + Methionine (0.5 %) + NADH (0.45 %) + Phosphoric acid (0.115 %) + Thiamine (0.02 %) + Tryptophan (1.1 %) + Tyrosine (0.1 %) + Valine (0.77 %) + Vitamin A (0.84 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 1990-01-16 2024-01-23 Turkey HEPATAMINE %8 500 ML(SETSIZ) Sodium bisulfite (0.01 %) + Ademetionine (0.24 %) + Adenine (0.8 %) + Ascorbic acid (0.6 %) + Aspartame (0.9 %) + Biotin (0.1 %) + Calcifediol (0.9 %) + Cysteine (0.066 %) + Lysine (0.61 %) + Methionine (0.5 %) + NADH (0.45 %) + Phosphoric acid (0.115 %) + Thiamine (0.02 %) + Tryptophan (1.1 %) + Tyrosine (0.1 %) + Valine (0.77 %) + Vitamin A (0.84 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 1990-01-16 2024-01-23 Turkey LIBAVIT-K 20 MG AMPUL, 5 ADET Sodium bisulfite (6 mg/2ml) + Menadione (20 mg/2ml) + Sodium chloride (12.6 mg/2ml) Injection, solution LİBA LABORATUARLARI A.Ş. 1980-09-22 Not applicable Turkey NEOFLEKS IZOPLEN-P % 5 DEKSTROZLU DENGELI ELEKTROLIT IÇEREN INFÜZYON IÇIN ÇÖZELTI 1000 ML SETLI Sodium bisulfite (0.021 g/100ml) + D-glucose (5.5 g/100ml) + Dipotassium phosphate (0.026 g/100ml) + Sodium lactate (0.26 g/100ml) + Magnesium chloride hexahydrate (0.031 g/100ml) + Potassium chloride (0.13 g/100ml) Solution Intravenous TURKTIPSAN SAĞLIK TURİZM EĞİTİM VE TİC. A.Ş. 2011-05-26 Not applicable Turkey NEOFLEKS IZOPLEN-P % 5 DEKSTROZLU DENGELI ELEKTROLIT IÇEREN INFÜZYON IÇIN ÇÖZELTI 1000 ML SETSIZ Sodium bisulfite (0.021 g/100ml) + D-glucose (5.5 g/100ml) + Dipotassium phosphate (0.026 g/100ml) + Sodium lactate (0.26 g/100ml) + Magnesium chloride hexahydrate (0.031 g/100ml) + Potassium chloride (0.13 g/100ml) Solution Intravenous TURKTIPSAN SAĞLIK TURİZM EĞİTİM VE TİC. A.Ş. 2011-05-26 Not applicable Turkey
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- TZX5469Z6I
- CAS number
- 7631-90-5
- InChI Key
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M
- InChI
- InChI=1S/Na.H2O3S/c;1-4(2)3/h;(H2,1,2,3)/q+1;/p-1
- IUPAC Name
- sodium hydrogen sulfite
- SMILES
- [Na+].OS([O-])=O
References
- General References
- TITCK Product Information: Hepatamine (Admetionine, Adenine, Ascorbic Acid, Aspartame, Biotin, Calcifediol, Cysteine, Lysine, Methionine, NADH, Phosphoric Acid, Sodium Bisulfite. Thiamine, Tryptophan, Tyrosine, Valine, Vitamin A) Intravenous Solution [Link]
- External Links
- ChemSpider
- 571016
- 1366858
- ChEBI
- 26709
- ChEMBL
- CHEMBL1689285
- Wikipedia
- Sodium_bisulfite
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Solution Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -1.2 Chemaxon pKa (Strongest Acidic) 1.7 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 60.36 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 11.21 m3·mol-1 Chemaxon Polarizability 5.43 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 114.43012 predictedDeepCCS 1.0 (2019) [M+H]+ 116.25029 predictedDeepCCS 1.0 (2019) [M+Na]+ 124.61406 predictedDeepCCS 1.0 (2019)
Drug created at April 25, 2018 22:30 / Updated at May 14, 2021 01:06